(Economic Observation) Xiamen is committed to creating a "life science and technology city"
China News Agency, Xiamen, June 7 (Reporter Yang Fushan) 2020 Xiamen Biomedicine Innovation and Development Conference was held on the 7th to promote the development of the biopharmaceutical industry and create a "life science and technology city".
After years of development, Xiamen's biopharmaceutical industry has become one of the country's strategic emerging industrial clusters; Xiamen is also accelerating industrial upgrading and accelerating development, striving to build a "life science and technology city" with strong competitiveness and industrial characteristics.
As early as 2003, the biopharmaceutical industry was listed by Xiamen City as one of the three strategic emerging industries. Over the years, it has grown into a gathering place for China's biomedicine industry. Since the "Twelfth Five-Year Plan", the average annual growth rate of the industrial output value of the biomedicine and health industries has exceeded 20%.
Official statistics show that as of the end of 2019, Xiamen has more than 800 related companies in the field of biomedicine and health industry, 297 state-level high-tech companies, and 10 biomedical companies listed on the Shanghai and Shenzhen A shares.
According to the Xiamen Municipal Science and Technology Bureau, the city’s biomedicine and health industry has formed local advantages and characteristics in the subdivision of new vaccines, genetically engineered protein drugs, in vitro diagnostics, hearing aids, orthopedic implant materials, respiratory consumables and other industries. And internationally leading innovative products.
Among them, Aide Bio-oncology accurate diagnostic products have entered the medical insurance catalogs of Japan, South Korea and other countries, and the high-end preparations of Lipin Pharmaceutical have entered the international market. Wantai Canghai and GlaxoSmithKline (GSK) have signed a global strategic cooperation agreement for a new generation of cervical cancer vaccines, building a vaccine production line in Xiamen that meets the standards of China, the United States, the European Union and the World Health Organization, and supplying global markets including Europe and the United States.
For many years, Xiamen City has always regarded the biomedicine and health industries as key supporting industries, and the effect of industrial agglomeration has become increasingly apparent. Since 2012, Xiamen has built the “Xiamen Biomedicine Port” with Haicang District as the core area, focusing on the development of innovative medicines, high-performance medical devices, emerging marine biotechnology, medical “new infrastructure” and other fields, and promoting the multiplied development of enterprises and investment attraction. Eight major projects including capacity expansion, platform base upgrade, clinical research collaboration, and demonstration application Huimin.
Since 2015, Xiamen City has successively issued biomedicine industrial policies, further increased support for the industry, focused on encouraging innovation and promoting industrialization, and all supporting funds are invested in key backbone enterprises and growth enterprises in key fields of the biopharmaceutical industry, with strong support The development of leading enterprises and the expansion of industrial scale.
Haicang District and Xiang'an District of Xiamen City have also issued relevant policies for industrial support, and the policies are superimposed and complementary to form a joint force. This year, the city has introduced several measures to accelerate the high-quality development of the biopharmaceutical industry. (Finish)